Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M | $90.6M | $214M | $287M | $374M | $450M | $564M | $739M | $982M |
| Revenue growth | — | 81.9% | 136.5% | 33.8% | 30.3% | 20.3% | 25.5% | 31.0% | 32.9% |
| Operating income | -$76.6M | -$92.9M | -$82.4M | -$255M | -$411M | -$544M | -$565M | -$444M | -$437M |
| Operating margin | -153.7% | -102.5% | -38.4% | -88.9% | -110.0% | -121.1% | -100.1% | -60.0% | -44.5% |
| Net income | -$83.2M | -$85.1M | -$75.7M | -$246M | -$385M | -$655M | -$479M | -$436M | -$416M |
| Net margin | -167.0% | -93.8% | -35.3% | -85.9% | -103.0% | -145.6% | -85.0% | -59.0% | -42.4% |
| EPS (diluted) | -$7.07 | -$2.80 | -$0.84 | -$2.60 | -$4.00 | -$6.41 | -$4.28 | -$3.56 | -$3.32 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$72.2M | -$72.2M | -$47.1M | -$104M | -$209M | -$309M | -$325M | -$240M | -$185M |
| Capital expenditures | $6.68M | $20.2M | $18.7M | $36.2M | $75.0M | $77.5M | $20.5M | $35.1M | $48.3M |
| Free cash flow | -$78.9M | -$92.4M | -$65.9M | -$140M | -$284M | -$387M | -$345M | -$275M | -$233M |
| Share buybacks | $7.22M | $172K | $0.00 | $0.00 | — | — | $0.00 | $0.00 | $45.0M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $72.3M | $141M | $143M | $833M | $492M | $142M | $1.13B | $526M | $378M |
| Total assets | $343M | $587M | $963M | $2.27B | $2.20B | $1.61B | $1.79B | $1.49B | $2.01B |
| Total liabilities | $34.3M | $62.5M | $115M | $916M | $1.56B | $1.55B | $1.63B | $1.63B | $2.11B |
| Long-term debt | — | — | — | — | — | — | — | $1.14B | $1.50B |
| Shareholders' equity | $309M | $483M | $798M | $1.30B | $645M | $60.2M | $159M | -$140M | -$99.3M |
| Retained earnings | -$196M | -$281M | -$353M | -$607M | -$1.01B | -$1.66B | -$2.14B | -$2.58B | -$2.99B |
| Shares (wtd avg diluted) | 11.9M | 85.8M | 90.6M | 97.5M | 101M | 102M | 112M | 123M | 125M |
Every figure is extracted from Guardant Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.